Page 134 - 202004
P. 134

群中的 PK 参数不尽相同,尽管部分研究已经给出了具                               of vancomycin in postoperative neurosurgical patients and
        体的给药方案推荐,但考虑到研究人群的样本量小、种                                 the application in dosing recommendation[J]. J Pharm
        族差异等因素,需要开展更多、更广泛的大样本研究来                                 Sci,2016,105(11):3425-3431.
        予以验证,以期为万古霉素的临床应用提供科学参考。                            [15]  LI X,SUN S,LING X,et al. Plasma and cerebrospinal flu-
        参考文献                                                     id populationpharmacokinetics of vancomycin in postoper-
        [ 1 ]  吴委.万古霉素群体药动学及个体化给药研究[D].福州:                       ative neurosurgical patients after combined intravenous
             福建医科大学,2013.                                        and intraventricular administration[J]. Eur J Clin Pharma-
        [ 2 ]  芮建中,张震,李金恒.群体药代动力学/群体药效动力学                        col,2017,73(12):1599-1607.
             原理及研究方法[J].医学研究生学报,2005,18(3):                 [16]  LIN WW,WU W,JIAO Z,et al. Population pharmacoki-
             246-249.                                            netics of vancomycinin adult Chinese patients with post-
        [ 3 ]  林忠,陈敏方,崔可,等.中国成年感染患者万古霉素群体                        craniotomy meningitis and its application in individu-
             药动学研究[J].中国现代应用药学,2017,34(1):105-                   alised dosage regimens[J]. Eur J Clin Pharmacol,2016,72
             110.                                               (1):29-37.
        [ 4 ]  陈冰,杨婉花,张伟霞,等.中国成年患者万古霉素群体药                   [17]  曾英彤,黄碧瑜,邱榆淇,等.老年透析ICU患者万古霉素
             动学研究[J].药学与临床研究,2013,21(6):605-609.                 群体药动学研究[C]//2017年广东省药师周大会论文集,
        [ 5 ]  DENG CH,LIU TT,ZHOU TY,et al. Initial dosage regi-  2017:949-964.
             mens of vancomycin for Chinese adult patients based on  [18]  ECONOMOU CJP,KIELSTEIN JT,CZOCK D,et al.
             population pharmacokinetic analysis[J]. Int J Clin Pharm  Population pharmacokinetics of vancomycin in critically
             Ther,2013,51(5):407-415.                            ill patients receiving prolonged intermittent renal replace-
        [ 6 ]  YASUHAR M,IGA T,ZENDA H,et al. Population phar-   ment therapy[J]. Int J Antimicrob Agents,2018,52(2):
             macokinetics of vancomycin in Japanese adult patients[J].  151-157.
             Ther Drug Monit,1998,20(2):139-148.            [19]  ESCOBAR L,ANDRESEN M,DOWNEY P,et al. Popu-
        [ 7 ]  YAMAMOTO M,KUZUYA T,BABA H,et al. Popula-         lation pharmacokinetics and dose simulation of vancomy-
             tion pharmacokinetic analysis of vancomycin in patients  cin in critically ill patients during high-volume haemofil-
             with grampositivein fections and the influence of infec-  tration[J]. Int J Antimicrob Agents,2014,44(2):163-167.
             tious disease type[J]. J Clin Pharm Ther,2009,34(4):  [20]  DONADELLO K,ROBERTS JA,CRISTALLINIS,et al.
             473-483.                                            Vancomycin population pharmacokinetics during extracor-
        [ 8 ]  PURWONUGROHO TA,CHULAVATNATO LS,PREE-             poreal membrane oxygenation therapy:a matched cohort
             CHAGOON Y,et al. Population pharmacokinetics of van-  study[J]. Crit Care,2014,18(6):1-10.
             comycin in Thai patients[J]. Scientific World J,2012. DOI:  [21]  杨薇,贺蓓,邓晨辉.下呼吸道感染重症患者万古霉素群
             10.1100/2012/762649.                                体药代动力学研究[J].中华结核和呼吸杂志,2017,40
        [ 9 ]  杨平,刘亚欧,时正媛,等.万古霉素在重症监护患者的群                       (3):205-209.
             体药代动力学模型建立与验证[J].中国临床药理学杂
                                                            [22]  ABRAHAM J,SINOLLAREDDY MG,ROBERTS MS,
             志,2018,34(6):656-659.
                                                                 et al. Plasma and interstitial fluid population pharmacoki-
        [10]  REVILLA N,MARTÍN-SUÁREZ A,PÉREZ MP,et al.
                                                                 netics of vancomycin in critically patients with sepsis[J].
             Vancomycin dosing assessment in intensive care unit pa-
                                                                 Int J Antimicrob Agents,2018,53(2):137-142.
             tients based on a population pharmacokinetic/pharmacody-
                                                            [23]  BUELGA DS,DEL MAR FERNANDEZDE GM,HER-
             namicsimulation[J]. Br J Clin Pharmacol,2010,70(2):
                                                                 RERA EV,et al. Population pharmacokinetic analysis of
             201-212.
                                                                 vancomycin in patients with hematological malignan-
        [11]  TURNER RB,KOJIRO K,WON R,et al. Prospective
                                                                 cies[J]. Antimicrob Agents Chemother,2006,49(12):
             evaluation of vancomycin pharmacokinetics in a heteroge-
                                                                 4934-4941.
             neous critically-ill population[J]. Diagn Microbiol Infect
                                                            [24]  MULLA H,POOBONI S. Population pharmacokinetics of
             Dis,2018,92(4):346-351.
                                                                 vancomycin in patients receiving extracorporeal mem-
        [12]  LIOPIS-SALVIA P,JIMÉNEZ-TORRES NV. Population
                                                                 brane oxygenation[J]. Br J Clin Pharmacol,2005,60(3):
             pharmacokinetic parameters of vancomycin in critically ill
                                                                 265-275.
             patients[J]. J Clin Pharm Ther,2006,31(5):447-454.
        [13]  LI X,WU Y,SUN S,et al. Population pharmacokinetics  [25]  AARONS L. Population pharmacokinetics:theory and pra-
             of vancomycin in postoperative neurosurgical patients[J]. J  ctice[J]. Br J Clin Pharmacol,2012,32(6):669-670.
             Pharm Sci,2015,104(11):3960-3967.                           (收稿日期:2019-04-11  修回日期:2020-01-09)
                                                                                                 (编辑:孙 冰)
        [14]  LI X,WU Y,SUN S,et al. Population pharmacokinetics

        ·508  ·  China Pharmacy 2020 Vol. 31 No. 4                                   中国药房    2020年第31卷第4期
   129   130   131   132   133   134   135   136   137   138   139